XML 75 R39.htm IDEA: XBRL DOCUMENT
v3.20.4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Aug. 05, 2019 EUR (€) | Aug. 05, 2019 USD ($) | Jun. 06, 2019 EUR (€) | Jun. 06, 2019 EUR (€) | Dec. 31, 2020 USD ($) Number $ / shares | Sep. 30, 2020 USD ($) | Dec. 31, 2020 USD ($) Number $ / shares | Dec. 31, 2019 USD ($) $ / shares | Dec. 31, 2018 USD ($) | Nov. 08, 2020 USD ($)
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Inventory charge |  |  |  |  |  | $ 5,700,000 | $ 7,204,818 | $ 0 |  |
Minimum cash balance requirement under credit agreement |  |  |  |  | $ 60,000,000 |  | 60,000,000 |  |  |
Cash FDIC insured amount |  |  |  |  | $ 250,000 |  | $ 250,000 |  |  |
Number of issued patents domestic. | Number |  |  |  |  | 38 |  | 38 |  |  |
Number of issued patents foreign | Number |  |  |  |  | 39 |  | 39 |  |  |
Write off of patent and trademark cost |  |  |  |  | $ 500,000 | $ 600,000 | $ 1,131,776 | $ 78,864 |  |
Common Stock, Par or Stated Value Per Share | $ / shares |  |  |  |  | $ 0.001 |  | $ 0.001 | $ 0.001 |  |
Amortization of intellectual property license fee |  |  |  |  |  |  | $ 3,024,391 | $ 778,692 |  |
Advertising expense |  |  |  |  |  |  | $ 35,799,313 | $ 9,045,571 | $ 1,682,746 |
Council License Agreement [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent |  |  |  |  |  |  | 50.00% |  |  |
Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent |  |  |  |  |  |  | 20.00% |  |  |
Maximum costs and expenses for post approval |  |  |  |  |  |  | $ 20,000,000 |  |  |
Council License Agreement Step 1 |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Royalty (percent) |  |  |  |  |  |  | 5.00% |  |  |
Council License Agreement Step 2 |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Royalty (percent) |  |  |  |  |  |  | 10.00% |  |  |
Council License Agreement Step 3 |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Royalty (percent) |  |  |  |  |  |  | 15.00% |  |  |
License Agreement Theramex [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Cash upfront payment received | € 14,000,000 | $ 15,506,400 |  |  |  |  |  |  |  |
Minimum [Member] | Council License Agreement Step 2 |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Net sales amount per step-based royalty |  |  |  |  |  |  | $ 500,000 |  |  |
Minimum [Member] | Council License Agreement Step 3 |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Net sales amount per step-based royalty |  |  |  |  |  |  | $ 1,500,000 |  |  |
Minimum [Member] | License Agreement Theramex [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Sales milestone | € |  |  | € 25,000,000 |  |  |  |  |  |  |
Maximum [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Return period of unsalable prescription products |  |  |  |  |  |  | 12 months |  |  |
Maximum [Member] | Council License Agreement Step 1 |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Net sales amount per step-based royalty |  |  |  |  |  |  | $ 500,000 |  |  |
Maximum [Member] | Council License Agreement Step 2 |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Net sales amount per step-based royalty |  |  |  |  |  |  | $ 1,500,000 |  |  |
Maximum [Member] | License Agreement Theramex [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Regulatory milestone payments | € |  |  | 2,000,000 | € 2,000,000 |  |  |  |  |  |
Sales milestone payment | € |  |  | 27,500,000 | € 27,500,000 |  |  |  |  |  |
Sales milestone | € |  |  | € 100,000,000 |  |  |  |  |  |  |
Land and Building [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Useful life of assets |  |  |  |  |  |  | 3 years |  |  |
Land and Building [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Useful life of assets |  |  |  |  |  |  | 7 years |  |  |
Software and Software Development Costs [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Useful life of assets |  |  |  |  |  |  | 5 years |  |  |
Software and Software Development Costs [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Useful life of assets |  |  |  |  |  |  | 7 years |  |  |
Customer A [Member] | Accounts Receivable [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  |  |  |  |  |  | 25.00% | 36.00% |  |
Customer B [Member] | Accounts Receivable [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  |  |  |  |  |  | 19.00% | 21.00% |  |
Customer C [Member] | Accounts Receivable [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  |  |  |  |  |  | 17.00% | 16.00% |  |
Customer D [Member] | Accounts Receivable [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  |  |  |  |  |  | 11.00% | 11.00% |  |
Financing Agreement Amendment No. 6 [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Minimum cash balance requirement under credit agreement before adjustment |  |  |  |  |  |  |  |  |  | $ 60,000,000
Minimum cash balance requirement under credit agreement |  |  |  |  |  |  |  |  |  | $ 45,000,000
BIJUVA [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Inventory charge |  |  |  |  |  |  | $ 7,204,818 |  |  |
ANNOVERA [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Return period of unsalable prescription products |  |  |  |  |  |  | 12 months |  |  |
ANNOVERA [Member] | Council License Agreement [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Milestone payment upon FDA Approval |  |  |  |  |  |  | $ 20,000,000 |  |  |
Milestone payments (payment after release of first commercial batch) |  |  |  |  |  |  | 20,000,000 |  |  |
License rights acquired |  |  |  |  |  |  | 20,000,000 |  |  |
Milestone payments upon specified levels of cumulative net sales |  |  |  |  |  |  | 40,000,000 |  |  |
Specified level one of cumulative net sales for milestone payments |  |  |  |  |  |  | 200,000,000 |  |  |
Specified level two of cumulative net sales for milestone payments |  |  |  |  |  |  | 400,000,000 |  |  |
Specified level three of cumulative net sales for milestone payments |  |  |  |  |  |  | $ 1,000,000,000 |  |  |
Vitamins, IMVEXXY and BIJUVA [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Shelf life of prescription products |  |  |  |  |  |  | 24 months |  |  |
BIJUVA and ANNOVERA [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Shelf life of prescription products |  |  |  |  |  |  | 18 months |  |  |
BIJUVA and ANNOVERA [Member] | Knight License Agreement [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Milestone payment received upon regulatory approval |  |  |  |  |  |  | $ 2,000,000 |  |  |
BIJUVA and ANNOVERA [Member] | License Agreement Theramex [Member] |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |
Quarterly royalty payments percentage |  |  |  | 5.00% |  |  |  |  |  |

X
- Definition The amount represents amortization of intellectual property license fee. + References No definition available. + Details
Name: | txmd_AmortizationOfIntellectualPropertyLicenseFee
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual net sale milestones in the Territory per license agreement. + References No definition available. + Details
Name: | txmd_AnnualNetSalesMilestone
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent. + References No definition available. + Details
Name: | txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S. + References No definition available. + Details
Name: | txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from license agreement. + References No definition available. + Details
Name: | txmd_CashUpfrontPaymentReceived
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement. + References No definition available. + Details
Name: | txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payment received upon regulatory approval. + References No definition available. + Details
Name: | txmd_MilestonePaymentReceivedUponRegulatoryApproval
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payments upon FDA approval. + References No definition available. + Details
Name: | txmd_MilestonePaymentUponFDAApproval
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of milestone payments payable after release of first commercial batch. + References No definition available. + Details
Name: | txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments due upon specified levels of cumulative net sales for under agreement. + References No definition available. + Details
Name: | txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The minimum cash balance the Borrower must maintain under the credit and secuirty agreement. + References No definition available. + Details
Name: | txmd_MinimumCashBalanceRequirementUnderCreditAgreement
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The minimum cash balance the Borrower must maintain under the credit and secuirty agreement before adjustment. + References No definition available. + Details
Name: | txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The net sales amount as defined in license agreement for step-based royalty payments. + References No definition available. + Details
Name: | txmd_NetSalesAmountPerStepbasedRoyalty
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of issued patents domestic. + References No definition available. + Details
Name: | txmd_NumberOfIssuedPatentsDomestic
Namespace Prefix: | txmd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of issued patents foreign. + References No definition available. + Details
Name: | txmd_NumberOfIssuedPatentsForeign
Namespace Prefix: | txmd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of quarterly royalty payments on net sales which the company is entitled to receive. + References No definition available. + Details
Name: | txmd_QuarterlyRoyaltyPaymentsPercentage
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets. + References No definition available. + Details
Name: | txmd_RegulatoryMilestoneAdditionalPayment
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Period the company accepts returns of unsalable prescription products from customers following product expiration. + References No definition available. + Details
Name: | txmd_ReturnPeriodOfUnsalablePrescriptionProducts
Namespace Prefix: | txmd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percent of the net sales to be paid as royalty per license agreement. + References No definition available. + Details
Name: | txmd_RoyaltyPercent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of sales milestone payments per licensing agreement. + References No definition available. + Details
Name: | txmd_SalesMilestonePaymentsInTranches
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Period shelf life of prescription products from date of manufacture. + References No definition available. + Details
Name: | txmd_ShelfLifeOfPrescriptionProducts
Namespace Prefix: | txmd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount represents specified level one of cumulative net sales for milestone payments. + References No definition available. + Details
Name: | txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount represents specified level three of cumulative net sales for milestone payments. + References No definition available. + Details
Name: | txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount represents specified level two of cumulative net sales for milestone payments. + References No definition available. + Details
Name: | txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -SubTopic 35 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848 + Details
Name: | us-gaap_AdvertisingExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation. + References No definition available. + Details
Name: | us-gaap_CashFDICInsuredAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314 + Details
Name: | us-gaap_InventoryWriteDown
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ProductInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_BijuvaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_AnnoveraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_VitaminsImvexxyAndBijuvaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_KnightLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |